If you wanted the swiftest Trial it would be a simple Human 14 patient Covid Trial , Tablets are approved for Human Trialing now with exceptional Safety and Tolerability Profile.. 14 patients in a Private Hospital , 10 day trial " You don't have Australia's leading Entomologist use terms like Remarkable" Mark Pelegrini has only used the term once.. on the results of the Covid Pre clinical trial,,, 99% reduction in Viral Load in 72 hours..
But agree ,, the other Neurodegenerative Disease Indications will be a catalyst but PAA have swathes of Preclinical data , mostly for Cancers. Never forget the Olivia Newton John Foundation trialed MPL across 30 Human Cancers , 28 responded positively to MPL...Plus we own the Patent already.
Correct Jock 2 Huge Catalysts dwarfed by Politics and Timing,, but non the less achieved,,, extracting SH value is no easy task ,,, certainly not achieved by accident, comes down to Investment , plain and simple... Company can still revisit those Catalysts.
For me the easiest way to achieve certain market breakthrough is "Commercial Valuation" a real one that's paid for through an independent 3rd party provider , reputable and comprehensive.
Company has shied away from utilising Hot Copper so you cant expect the same market reaction to News that Paid Content and HC Corporate Sponsors enjoy... remember HC survives off of those Corporate Sponsor Companies... thats why their News is turned into Feature articles on the Home page and last several days and not just washed off the list..
My opinion is we have been driving around the last 3 months (since the BOD spill and restructure) with the hand brake on and dragging an anchor..
New Team , New Management Style so lets see what the new kids on the block have up their sleeves.. IMHO PAA hasn't even been noted Market Wide the previous BOD treated the Company like a Research Institute,, the New management have referenced more toward value in the past 6 months than previous management mentioned in 10 years..
IMHO we should run back to circa 30c quite swiftly ,, if not then Investors will look for returns elsewhere ,, once the main Catalysts are expended then the erosion over time begins , simply comes down to managements desire and ability to place PAA in front of investors and demonstrate PAA is a Significant Commercial Opportunity and an Investment that will pay handsomely... 212 Biotechs and baby Pharma so plenty of choice elsewhere and today at the click of a button SH can move on... from my correspondence with MT " He certainly understands the game" But Update and news droughts effect Companies especially when there are choices.... you know me ,, I'm only here for the returns , one of my other Bio's has increased 200% in 40 days so it can be done..
(20min delay)